Crescent Sterling’s Regeneron Pharmaceuticals REGN Stock Holding History

Crescent Sterling’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-279	Closed	-$215K	–	83
2025 Q4	$215K	Buy	+279	New	+$189K	0.22%	75
2025 Q2	–	Sell	-411	Closed	-$261K	–	78
2025 Q1	$261K	Buy	411 +9	+2%	+$6.19K	0.27%	69
2024 Q4	$286K	Sell	402 -15	-4%	-$12.6K	0.29%	67
2024 Q3	$438K	Sell	417 -16	-4%	-$17.8K	0.42%	56
2024 Q2	$455K	Hold	433	–	–	0.44%	57
2024 Q1	$417K	Sell	433 -7	-2%	-$6.66K	0.38%	58
2023 Q4	$386K	Hold	440	–	–	0.39%	57
2023 Q3	$362K	Sell	440 -19	-4%	-$14.9K	0.38%	56
2023 Q2	$330K	Hold	459	–	–	0.31%	60
2023 Q1	$377K	Buy	459 +16	+4%	+$12.1K	0.37%	56
2022 Q4	$320K	Buy	+443	New	+$327K	0.34%	55

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Crescent Sterling's REGN Position: Q1 2026 in Review

Crescent Sterling sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 279 shares — an estimated $215K sold.

Crescent Sterling first reported a position in REGN in Q4 2022 and held it in 11 quarters. The position peaked at $455K in Q2 2024. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Crescent Sterling reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Crescent Sterling sold 279 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $215K.
Crescent Sterling first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Crescent Sterling's Regeneron Pharmaceuticals position peaked at $455K in Q2 2024.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Crescent Sterling's 13F filing for Q1 2026, filed 7 Apr 2026.